Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravenous mFOLFOX7 Plus Camrelizumab and Apatinib for CNLC Stage III Hepatocellular Carcinoma

Next Previous
X
Search
Trial Profile

Intravenous mFOLFOX7 Plus Camrelizumab and Apatinib for CNLC Stage III Hepatocellular Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 04 Jun 2024 Results (n=35) assessing safety and efficacy of venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2023 Results (data cut off Jan 31, 2023) assessing efficacy and safety profile of VIC with apatinib and camrelizumab for CNLC stage III HCC presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 14 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top